The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
September 27, 2017
Florida statute requires individuals who were fingerprinted on or after Jan. 1, 2013 to have their background results retained in Florida’s Care Provider Background Screening Clearinghouse. Continue reading
September 13, 2017
Due to impacts from Hurricane Irma, Governor Scott has issued an executive order regarding the state of Florida Continue reading